Related Experiment Videos
Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered
Abstract:
Twenty-four patients with various solid tumors including metastatic liver cancer and cancer of the lung, gallbladder, and pancreas were treated with a lipophilic macromolecular drug, copoly(styrene-maleic acid) conjugated neocarzinostatin (SMANCS). The drug was dissolved in a lipid contrast medium Lipiodol and administered by catheterizing the respective feeding arteries under x-ray monitoring. The advantages of this therapy include: (1) selective deposition of Lipiodol with the anti-cancer drug in the target tumor, (2) a pronounced and long-lasting anti-cancer effect, (3) enhanced visualization of the tumor on x-ray examinations for a prolonged period which also facilitated the long-term follow-up, (4) semiquantitative evaluation of the dosage regimen by x-ray examination before further administration, (5) general applicability due to procedural simplicity, and (6) little side effect. Since the amount of Lipiodol and SMANCS used per administration for a patient (1.0-5.0 ml; 1.0-5.0 mg) was far less than the anticipated toxicity (LD50 of Lipiodol = 95 ml/60 kg, dog, intravenously; and that of SMANCS = 3.4 mg/kg, mouse, IV), no deleterious effects to such critical organs as the brain, heart, lung, liver, or kidneys were observed upon radiologic and general clinical examination.
Insights
This study shows that a new cancer treatment using copoly(styrene-maleic acid) conjugated neocarzinostatin (SMANCS) delivered via Lipiodol offers targeted tumor deposition and a lasting anti-cancer effect with minimal side effects.
Area of Science:
- Oncology
- Radiology
- Drug Delivery Systems
Background:
- Solid tumors, including metastatic liver, lung, gallbladder, and pancreatic cancers, present significant treatment challenges.
- Conventional therapies often have limitations in targeting efficacy and systemic toxicity.
Purpose of the Study:
- To evaluate the safety and efficacy of a novel lipophilic macromolecular drug, copoly(styrene-maleic acid) conjugated neocarzinostatin (SMANCS), for solid tumor treatment.
- To assess the benefits of SMANCS delivery using Lipiodol via arterial administration under X-ray monitoring.
Main Methods:
- Twenty-four patients with various solid tumors received SMANCS dissolved in Lipiodol.
- Administration was performed via catheterization of feeding arteries under X-ray guidance.
- Tumor visualization and dosage were monitored using X-ray examinations.
Main Results:
- Selective deposition of Lipiodol and SMANCS within target tumors was achieved.
- A pronounced and sustained anti-cancer effect was observed.
- Enhanced tumor visualization facilitated long-term follow-up and dosage evaluation.
- No significant adverse effects on critical organs were noted due to low administered doses relative to toxicity thresholds.
Conclusions:
- This SMANCS-Lipiodol therapy demonstrates general applicability, procedural simplicity, and a favorable safety profile.
- The treatment offers a promising approach for managing various solid tumors with targeted drug delivery and prolonged therapeutic effects.